NASDAQ · CARL
Carlsmed, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CARL: Nov 10, 2026
Carlsmed, Inc. Common Stock is expected to report earnings on 11/10/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.41. The reported EPS for the same quarter last year was $-0.4.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.41 | $-0.41 | $-0.42 | 2 |
| Dec 2026 | $-0.41 | $-0.41 | $-0.41 | 1 |
| Mar 2027 | $-0.37 | $-0.37 | $-0.37 | 1 |
| Jun 2027 | $-0.39 | $-0.39 | $-0.39 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · MarketBeat · Zacks- RTTNews · Oct 14, 11:02 AM EDTCarlsmed Debuts New Spine Fusion Technology Designed For 3D Correction(RTTNews) – Carlsmed Inc. (CARL), a medical technology company developing AI-enabled personalized spine surgery solutions, announced the U.S. commercial launch of its aprevo Lumbar Bi-lateral Posterior System at the North American Spine Society's 41st Annual Meeting (NASS) in San
- RTTNews · Sep 28, 8:58 AM EDTCarlsmed Appoints Richard Heppenstall As CFO; Backs Annual Revenue Outlook(RTTNews) – Carlsmed, Inc. (CARL), a medical technology company, said on Monday that it has appointed Richard Heppenstall as chief financial officer with immediate effect. Heppenstall will succeed Leo Greenstein, who has decided to leave the company to pursue other professional o
- RTTNews · Sep 9, 2:15 AM EDTCarlsmed Promotes Jeff Bertolini To Chief Operating Officer(RTTNews) – Carlsmed Inc. (CARL), a medical technology company, announced the promotion of Jeff Bertolini to Chief Operating Officer, effective immediately, from his role as Senior Vice President, Operational Excellence.
- MarketBeat · Aug 12, 9:04 PM EDTCarlsmed Eyes Growth as Cervical Launch, Medicare Shift Boost Spine PlatformCarlsmed (NASDAQ:CARL) outlined its strategy for expanding its personalized spine-surgery platform, citing clinical data, reimbursement changes and a planned cervical product launch as potential drivers of growth during a Bank of America small- and mid-cap virtual event. Chief E
- MarketBeat · Aug 5, 8:04 PM EDTCarlsmed Q2 Earnings Call HighlightsCarlsmed (NASDAQ:CARL) reported second-quarter 2026 revenue of $18.9 million, up 57% from $12.1 million a year earlier, as growth in its aprevo lumbar platform and contributions from its newer cervical offering lifted procedure volumes. Chairman and Chief Executive Officer Mike
- Zacks · Aug 5, 6:10 PM EDTCarlsmed, Inc. (CARL) Reports Q2 Loss, Beats Revenue EstimatesCarlsmed, Inc. (CARL) delivered earnings and revenue surprises of +2.50% and +2.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 30, 6:00 PM EDTFulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Misses Revenue EstimatesFulgent Genetics (FLGT) delivered earnings and revenue surprises of -26.09% and -9.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 30, 10:00 AM EDT10x Genomics (TXG) Expected to Beat Earnings Estimates: Can the Stock Move Higher?10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Jul 29, 10:00 AM EDTWill Carlsmed, Inc. (CARL) Report Negative Earnings Next Week? What You Should KnowCarlsmed, Inc. (CARL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · May 25, 9:55 AM EDTWall Street Analysts See a 51.94% Upside in Carlsmed, Inc. (CARL): Can the Stock Really Move This High?The consensus price target hints at a 51.9% upside potential for Carlsmed, Inc. (CARL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- Zacks · May 22, 9:40 AM EDTIs Align Technology (ALGN) Stock Outpacing Its Medical Peers This Year?Here is how Align Technology (ALGN) and Carlsmed, Inc. (CARL) have performed compared to their sector so far this year.
- Zacks · May 8, 9:55 AM EDTWall Street Analysts Think Carlsmed, Inc. (CARL) Could Surge 90.77%: Read This Before Placing a BetThe mean of analysts' price targets for Carlsmed, Inc. (CARL) points to a 90.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Carlsmed, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.